Contribution: Industrial Research Assistance Program – Contributions to Firms
Primary Peptides Inc.
$218,981.00
Development of a longer acting peptide targeting TDP-43 as a candidate therapeutic for amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD) treatment
FY 2023-24 · 2023-05-01
Summary
The Project will support, in part, development of long-acting candidate peptide therapeutics targeting aberrant TDP-43.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Victoria|Victoria, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
850988379
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2023-05-01 | 2023-24 | $209,462.00 |
| 1 | 2023-05-01 | 2023-24 | $209,462.00 |
| 3 | 2023-05-01 | 2023-24 | $209,462.00 |
| 4 | 2023-05-01 | 2023-24 | $218,981.00 |
| 5 | 2023-05-01 | 2023-24 | $218,981.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 61 jours.
Agreement End Date
2025-06-30
Agreement Number
1006420
Agreement Start Date
2023-05-01
Agreement Title
Development of a longer acting peptide targeting TDP-43 as a candidate therapeutic for amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD) treatment
Agreement Title (French)
Développement d’un peptide à action prolongée ciblant le TDP-43 en tant que candidat thérapeutique pour le traitement de la sclérose latérale amyotrophique (SLA) et de la démence fronto-temporale (DFT).
Agreement Type
Contribution
Agreement Value
$218,981.00
Amendment Date
2025-03-28
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The Project will support, in part, development of long-acting candidate peptide therapeutics targeting aberrant TDP-43.
Description (French)
Le projet soutiendra, en partie, le développement de peptides thérapeutiques candidats à longue durée d’action ciblant le TDP-43 aberrant.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Saanich--Gulf Islands
Federal Riding (French)
Saanich--Gulf Islands
Federal Riding Number
59027
NAICS Code
9119
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
850988379
Recipient City
Victoria|Victoria
Recipient Country
CA
Recipient Legal Name
Primary Peptides Inc.
Recipient Postal Code
V8N 3V1
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2023-2024-Q1-1006420
